​
​

Prometheus Biosciences Ownership | Who Owns Prometheus Biosciences?

OverviewForecastChart

Prometheus Biosciences Ownership Summary

Prometheus Biosciences is owned by 0.05% institutional investors, and 99.95% retail investors. Vanguard Instl Ttl Stck Mkt Idx Tr is the top mutual fund, with 2.28% of its assets in Prometheus Biosciences shares.

RXDX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockPrometheus Biosciences0.05%-99.95%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20233-98.74%25,622-99.94%-0.00%--100.00%--100.00%
Mar 31, 2023239-1.65%40,539,5676.56%851.09%131-22.49%7457.45%
Dec 31, 202224358.82%38,044,84315.85%881.40%16972.45%4756.67%
Sep 30, 202215328.57%32,840,2436.63%791.29%9848.48%30-16.67%
Jun 30, 202211913.33%30,799,70911.39%781.56%6611.86%3620.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Instl Ttl Stck Mkt Idx Tr1.09M2.28%28.93K
Eventide Healthcare & Life Sciences I470.02K0.98%-362.92K
Fidelity® Small Cap Index304.67K0.64%5.01K
Eventide Gilead N200.00K0.42%-
Alger Capital Appreciation Instl I132.78K0.28%-10.04K
Alger Capital Appreciation B111.83K0.23%-3.70K
Arbitrage R95.48K0.20%95.48K
T. Rowe Price US Smlr Cm Eq A USD60.68K0.13%618.00
iShares Russell 2000 Small-Cap Idx Instl48.03K0.10%1.73K
Empower Small Cap Growth/TimesSquare SP47.00K0.10%47.00K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 05, 2023Marshall Keith W Chief Financial OfficerSell$1.08M
Mar 15, 2023McKenna Mark C. Chairman, President & CEOSell$2.90M
Mar 06, 2023Marshall Keith W Chief Financial OfficerSell$1.22M
Mar 08, 2023Cedars Sinai Intellectual Property Co-Sell$99.12M
Mar 01, 2023McKenna Mark C. Chairman, President & CEOSell$87.68K

Insider Transactions Trends

DateBuySell
2023 Q2-1
2023 Q1-11
2022 Q4--
2022 Q2--
2021 Q4--

RXDX Ownership FAQ

Who Owns Prometheus Biosciences?

Prometheus Biosciences shareholders are primarily institutional investors at 0.05%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Prometheus Biosciences's industry, Biotech Stocks , is 44.97%, which Prometheus Biosciences falls below.

Does Blackrock own Prometheus Biosciences?

BlackRock is not among the top 10 institutional shareholders of Prometheus Biosciences.

Who is the top mutual fund holder of Prometheus Biosciences shares?

Vanguard Instl Ttl Stck Mkt Idx Tr is the top mutual fund holder of Prometheus Biosciences shares, with 2.28% of its total shares outstanding invested in 1.09M Prometheus Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools